Ilika plc ((GB:IKA)) has held its Q4 earnings call. Read on for the main highlights of the call.
Ilika plc’s latest earnings call struck a cautiously optimistic tone as management highlighted clear technical progress and first commercial revenues, but also underscored lingering financial constraints and execution risks. The mood balanced confidence in the company’s solid‑state battery technology with realism about modest current income and the need for further funding to reach meaningful scale.
Stable Revenue with First Stereax Sales
Ilika reported full‑year revenue of £1.1m, unchanged year‑on‑year, but with an important qualitative shift as it booked its first commercial Stereax wafer and electrode revenues. Around £100k of Stereax sales marked a move from pure R&D towards revenue‑generating activity, and management expects these miniature solid‑state battery sales to build through the current financial year.
Grants and Fresh Capital Support Development
Grant income remained material at about £1.0m, supported by awards from the U.K. Battery Innovation Programme and the Advanced Propulsion Centre. Management also pointed to a recent top‑up equity raise completed after year‑end, arguing that grant funding effectively leverages shareholder capital by co‑financing R&D, commercialization and scale‑up efforts.
Stereax Commercialization and Cirtec Partnership
Production of the Stereax M300 line has begun, with deliveries to paying customers and revenue from wafers flowing through a licensing and profit‑share deal with U.S. manufacturer Cirtec. Cirtec’s wafer‑scale and U.S. manufacturing footprint provides a route to faster adoption and credible volume scale‑up, while Ilika retains electrode production know‑how and wafer‑related revenue streams.
Goliath Prototypes and Early Market Pathways
Automation of Ilika’s Goliath megawatt‑hour pilot line has been completed and 10A prototype cells are now in the hands of automotive and non‑automotive partners. Collaborations with Jaguar Land Rover’s battery venture Agratas, Brompton in e‑bikes and a defense advisory body have delivered positive validation, and Ilika is converting the 10A design into a minimum viable product aimed at early commercial wins in defense, e‑bikes and select industrial markets.
Pilot Line Capacity and Gigafactory Compatibility
The company’s pilot facility offers roughly 1.5 MWh per year of output, enough for up to about 20,000 10Ah cells, which is suitable for prototyping and niche commercial applications. Work with the U.K. Battery Industrialisation Centre has shown Ilika’s chemistry and design can run on larger gigafactory‑scale equipment, helping reduce perceived integration risk for potential licensees considering long‑term partnerships.
Strong Intellectual Property and Technical Edge
Ilika now holds 88 granted patents across key jurisdictions, bolstering its defensive moat in solid‑state technologies. The company highlighted modeled benefits for a Hyundai Ioniq 5 using Goliath cells, including roughly 20% vehicle weight and range improvement and a charge‑time cut from 18 to 12 minutes, together with safety and penetration resilience demonstrated in defense‑related testing.
Revenue Still Modest and Concentrated
Despite the strategic importance of first Stereax sales, overall revenue remains small relative to market ambitions and investor expectations. Commercial income is concentrated, with Stereax contributing only about £100k during the year and the bulk of the £1.1m top line still coming from grants rather than diversified product sales.
Losses Widen as Investment Intensifies
EBITDA losses rose to £6.2m from £5.2m, a near 19% year‑on‑year increase, and loss per share climbed to 4.02p from 3.50p. Management attributed the deeper losses partly to heavier material use in producing 10A Goliath prototypes and an accounting change that expenses Stereax development costs now that the product line has entered the revenue‑generating phase.
Thin Cash Buffer and Funding Dependence
Year‑end cash stood at £5.3m, with management noting that a further cash raise was completed in July to strengthen the balance sheet. Even with that top‑up, Ilika remains reliant on a mix of non‑dilutive grants, industrial partnerships and periodic capital raises to fund ongoing validation work and the transition from pilot production to more meaningful commercial volumes.
Resource Limits Shape Strategy Choices
Given finite engineering and financial resources, Ilika has chosen to prioritize the commercialization of its 10A Goliath prototype over further development of a larger 50A cell. This defers a potentially bigger product opportunity in high‑energy automotive formats, illustrating how near‑term capital and capacity constraints can narrow product breadth and push out timelines.
Pilot Scale and Slow Automotive Validation
Management emphasized that the current pilot line, while adequate for testing and small‑scale commercial uses, is far from the gigascale capacity required for mainstream automotive adoption. Automotive validation cycles, including long‑duration life testing, are inherently slow, and licensing deals are expected to follow option‑and‑validation phases that delay the arrival of large, recurring revenue streams.
Market, IP and Partner Dependence Risks
The company acknowledged risks around potential IP leakage and copying, particularly from lower‑cost Chinese competitors, and the broader geopolitical backdrop. Ilika’s commercial model also leans heavily on key partners such as Cirtec, Agratas and various OEMs, while future grant income is far from guaranteed given oversubscribed funding competitions.
Guidance: Transition Toward Commercial Traction
Looking ahead, management portrays Ilika as transitioning to revenue generation across both its Goliath large‑format and Stereax miniature lines, underpinned by existing grants and pilot infrastructure. With 16 Stereax customers, 19 orders, active MVP work on 10A Goliath cells, and modeled performance gains, the company expects further grant support and option‑to‑license milestones to gradually convert technical validation into scalable commercial agreements.
Ilika’s earnings call paints the picture of a technology‑rich battery player taking early but tangible steps toward commercialization, buttressed by partnerships and grant backing. For investors, the story is one of promising solid‑state progress and growing customer interest, set against widening losses, funding needs and long lead times before gigafactory‑scale revenues can realistically emerge.